share_log

Panbela Therapeutics | 25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)

Panbela Therapeutics | 25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)

Panbela Therapeutics | 25-NSE:由交易所申報的註銷已到期、已贖回、已兌付證券的通知
美股sec公告 ·  04/25 09:15
Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc., listed on the Nasdaq Stock Market, is set to be removed from listing effective May 6, 2024. The decision comes after a series of evaluations by Nasdaq Staff, which concluded that the company no longer meets certain listing requirements, specifically those under Listing Rules 5550(a)(2) and 5550(b)(1). Panbela Therapeutics was initially notified of the potential delisting on November 28, 2023, and subsequently requested a hearing on December 5, 2023. Despite receiving an additional delisting determination on January 22, 2024, for failing to meet the requirements of Listing Rule 5550(a)(4), the company's appeal to remain listed was denied by the Panel on March 5, 2024. Following a suspension of its securities on March 7, 2024, the company's request for reconsideration was also denied on March 15, 2024. With no further appeals made to the Nasdaq Listing and Hearing Review Council, the Staff's decision to delist became final on April 19, 2024.
Panbela Therapeutics, Inc., listed on the Nasdaq Stock Market, is set to be removed from listing effective May 6, 2024. The decision comes after a series of evaluations by Nasdaq Staff, which concluded that the company no longer meets certain listing requirements, specifically those under Listing Rules 5550(a)(2) and 5550(b)(1). Panbela Therapeutics was initially notified of the potential delisting on November 28, 2023, and subsequently requested a hearing on December 5, 2023. Despite receiving an additional delisting determination on January 22, 2024, for failing to meet the requirements of Listing Rule 5550(a)(4), the company's appeal to remain listed was denied by the Panel on March 5, 2024. Following a suspension of its securities on March 7, 2024, the company's request for reconsideration was also denied on March 15, 2024. With no further appeals made to the Nasdaq Listing and Hearing Review Council, the Staff's decision to delist became final on April 19, 2024.
在納斯達克股票市場上市的Panbela Therapeutics, Inc. 定於2024年5月6日起停止上市。該決定是在納斯達克工作人員進行了一系列評估之後做出的,評估得出的結論是,該公司不再符合某些上市要求,特別是《上市規則》5550(a)(2)和5550(b)(1)的要求。Panbela Therapeutics最初於2023年11月28日收到可能的退市通知,隨後要求在2023年12月5日舉行聽證會。儘管該公司因未能符合《上市規則》第5550 (a) (4) 條的要求而於2024年1月22日收到了額外的除牌決定,但該小組仍於2024年3月5日駁回了該公司繼續上市的上訴。繼2024年3月7日暫停證券後,該公司的重審請求也於2024年3月15日被拒絕。由於沒有向納斯達克上市和聽證會審查委員會提出進一步上訴,工作人員的退市決定於2024年4月19日成爲最終決定。
在納斯達克股票市場上市的Panbela Therapeutics, Inc. 定於2024年5月6日起停止上市。該決定是在納斯達克工作人員進行了一系列評估之後做出的,評估得出的結論是,該公司不再符合某些上市要求,特別是《上市規則》5550(a)(2)和5550(b)(1)的要求。Panbela Therapeutics最初於2023年11月28日收到可能的退市通知,隨後要求在2023年12月5日舉行聽證會。儘管該公司因未能符合《上市規則》第5550 (a) (4) 條的要求而於2024年1月22日收到了額外的除牌決定,但該小組仍於2024年3月5日駁回了該公司繼續上市的上訴。繼2024年3月7日暫停證券後,該公司的重審請求也於2024年3月15日被拒絕。由於沒有向納斯達克上市和聽證會審查委員會提出進一步上訴,工作人員的退市決定於2024年4月19日成爲最終決定。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息